Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;60(9):e382.
doi: 10.1111/ijd.15524. Epub 2021 Mar 14.

Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients

Yu Wang  1 , Joseph Jorizzo  2   3
Affiliations

Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients

Yu Wang et al. Int J Dermatol. 2021 Sep.
No abstract available

PubMed Disclaimer

References

    1. Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy 2020; 50: 5-14.
    1. Chu CY. Keeping an eye on the ocular problems in dupilumab clinical trials. Br J Dermatol 2019; 181: 436-437.
    1. Food and Drug Administration. Food and Drug Administration Adverse Event Reporting System [database]. Retrieved from https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet....
    1. Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018; 6: 1778-1780 e1.
    1. Akinlade B, Teper A, Staudinger H, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459-473.

Substances